| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0015 | 1 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.0014 | 1 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.0013 | 1 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0011 | 1 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.00092 | 1 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.00095 | 1 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.00085 | 1 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.00077 | 1 |